UK Firms Give First Appraisal Of New Licensing & Access Pathway
Concrete examples of how the UK’s ILAP is working in practice are still thin on the ground, but the general experience of companies so far seems quite positive – albeit with caveats.
You may also be interested in...
The UK’s ILAP, a post-Brexit scheme introduced in 2021 to accelerate the development of, and access to, new innovative medicines, proved popular in its first year of operation. A total of 71 applications were received last year from companies wanting to take advantage of the regulatory advice, tools and flexibilities on offer.
The MHRA intends to drop around 300 roles as it faces a financial crunch after leaving the EU and other pressures.
The joint action on ensuring security of medicines supply will be supported by the EU regulators’ shortages task force, which is to track efforts to coordinate member state activities on the supply and availability of medicines.